RFN-Advanced Retrograde Femoral Nailing System
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Dec 19, 2022
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subjects 18 years or older at the time of index procedure
- • 2. Subjects who received the Depuy Synthes Advanced Retrograde Nail in accordance with the indications for use.
- • 3. Subjects who have at least 6 months of follow-up.
- Exclusion Criteria:
- • Subject with less than 6 months of follow up, pathologic fractures, and patients \< 18 years of age will be excluded from the study.
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Patients applied
Trial Officials
Clay Spitler, MD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials